S 5682

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 581223

CAS#: 111804-73-0

Description: S 5682 is a purified flavonoid fraction composed of 90% diosmin 7-rhamnoglucoside and 10% hesperidin 7-rhamnoglucosid. Chemical name matches: detralex methotrexate. S 5682 has anti-oedematous effect anti-inflammatory properties.


Chemical Structure

img
S 5682
CAS# 111804-73-0

Theoretical Analysis

MedKoo Cat#: 581223
Name: S 5682
CAS#: 111804-73-0
Chemical Formula: C56H66O30
Exact Mass:
Molecular Weight: 1219.11
Elemental Analysis: C, 55.17; H, 5.46; O, 39.37

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: S 5682; Arvenum 500; Capiven; Detralex; S-5682; S5682; Venitol; detralex methotrexate;

IUPAC/Chemical Name: (S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)chroman-4-one compound with 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one (1:1)

InChi Key: UPZXYHXBFVZRHQ-RSZBNIDCSA-N

InChi Code: InChI=1S/C28H34O15.C28H32O15/c2*1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-7,10,17,19,21-30,32-37H,8-9H2,1-2H3;3-8,10,19,21-30,32-37H,9H2,1-2H3/t10-,17-,19+,21-,22+,23+,24-,25+,26+,27+,28+;10-,19+,21-,22+,23+,24-,25+,26+,27+,28+/m00/s1

SMILES Code: O1[C@H]([C@@H]([C@@H]([C@H]([C@@H]1C)O)O)O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)Oc1cc(c2c(c1)oc(cc2=O)c1ccc(c(c1)O)OC)O)O)O)O.O1[C@H]([C@@H]([C@@H]([C@H]([C@@H]1C)O)O)O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)Oc1cc(c2c(c1)O[C@@H](CC2=O)c1ccc(c(c1)O)OC)O)O)O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 1219.11 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Di Perri T, Auteri A. Action of S 5682 on the complement system. In vitro and in vivo study. Int Angiol. 1988 Apr-Jun;7(2 Suppl):11-5. PubMed PMID: 3183451.

2: Bouskela E, Svensjö E, Cyrino FZ, Lerond L. Oxidant-induced increase in vascular permeability is inhibited by oral administration of S-5682 (Daflon 500 mg) and alpha-tocopherol. Int J Microcirc Clin Exp. 1997;17 Suppl 1:18-20. PubMed PMID: 9477040.

3: Godfraind T. Effect of a flavonoid preparation (S 5682) on experimental capillary permeability increase in rat paw and rabbit skin. Int Angiol. 1988 Apr-Jun;7(2 Suppl):17-9. PubMed PMID: 3183452.

4: Galley P, Thiollet M. A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility. Int Angiol. 1993 Mar;12(1):69-72. PubMed PMID: 8376915.

5: Bouskela E, Cyrino FZ, Lerond L. Microvascular reactivity after ischemia/reperfusion in the hamster cheek pouch: beneficial effects of different oral doses of S-5682 (Daflon 500 mg). Angiology. 1997 Jan;48(1):33-7. PubMed PMID: 8995341.

6: Vargaftig BB. Biochemical mediators involved in the inflammatory reaction. Protective activity of S 5682. Int Angiol. 1988 Apr-Jun;7(2 Suppl):7-9. PubMed PMID: 3141532.

7: Poliantsev AA, Frolov DV, Linchenko DV, Shchelokova IuV. [Application of rivaroxabane in patients with proteins C and S deficiency]. Khirurgiia (Mosk). 2014;(9):68-71. Russian. PubMed PMID: 25327750.

8: Bouskela E, Cyrino FZ, Lerond L. Leukocyte adhesion after oxidant challenge in the hamster cheek pouch microcirculation. J Vasc Res. 1999;36 Suppl 1:11-4. PubMed PMID: 10474046.

9: Lonchampt M, Guardiola B, Sicot N, Bertrand M, Perdrix L, Duhault J. Protective effect of a purified flavonoid fraction against reactive oxygen radicals. In vivo and in vitro study. Arzneimittelforschung. 1989 Aug;39(8):882-5. PubMed PMID: 2818676.

10: Guillot R, Ogneva V, Hadjiisky P, Kassab JP, Andre J, Mozère G, Peyroux J, Sternberg M. Effect of long-term treatment with a purified micronized flavonoid fraction on pancreatic mononuclear cell infiltration in diabetic BB rats. Pancreas. 1998 Oct;17(3):301-8. PubMed PMID: 9788546.

11: Bouskela E, Donyo KA. Effects of oral administration of purified micronized flavonoid fraction on increased microvascular permeability induced by various agents and on ischemia/reperfusion in diabetic hamsters. Int J Microcirc Clin Exp. 1995 Nov-Dec;15(6):293-300. PubMed PMID: 8721438.

12: Bouskela E, Donyo KA. Effects of oral administration of purified micronized flavonoid fraction on increased microvascular permeability induced by various agents and on ischemia/reperfusion in the hamster cheek pouch. Angiology. 1997 May;48(5):391-9. PubMed PMID: 9158383.

13: Pietrzycka A, Kózka M, Urbanek T, Stpniewski M, Kucharzewski M. Effect of Micronized Purified Flavonoid Fraction Therapy on Endothelin-1 and TNF-α Levels in Relation to Antioxidant Enzyme Balance in the Peripheral Blood of Women with Varicose Veins. Curr Vasc Pharmacol. 2015;13(6):801-8. PubMed PMID: 26311575.

14: Korzhyk NP. [VARICOSE DISEASE OF THE LOWER EXTREMITIES: CAUSES, COMPLICATIONS, CHOICE OF METHODS FOR TREATMENT AND PROPHYLAXIS]. Klin Khir. 2016 Feb;(2):52-5. Ukrainian. PubMed PMID: 27244921.

15: Bogachev VY, Boldin BV, Lobanov VN, Arkadan NR, Ermak MY. [Adjuvant phlebotrophic therapy and its effect on anti-inflammatory response after sclerotherapy]. Angiol Sosud Khir. 2016;22(4):90-95. Russian. PubMed PMID: 27935886.

16: Tsukanov YT, Nikolaichuk AI. [Transitory (evening) venous reflux in patients with intracutaneous varicosity and medicamentous correction thereof]. Angiol Sosud Khir. 2016;22(2):110-6. Russian. PubMed PMID: 27336342.

17: Zubarev AR, Krivosheeva NV, Demidova aK, Rychkova IV. [Ultrasound elastography in assessing efficacy of treatment for lower limb varicose veins with a phlebotrophic drug containing a micronized purified flavonoid fraction]. Angiol Sosud Khir. 2014;20(2):90-6. Russian. PubMed PMID: 24961330.

18: Damon M, Flandre O, Michel F, Perdrix L, Labrid C, Crastes de Paulet A. Effect of chronic treatment with a purified flavonoid fraction on inflammatory granuloma in the rat. Study of prostaglandin E2 and F2 alpha and thromboxane B2 release and histological changes. Arzneimittelforschung. 1987 Oct;37(10):1149-53. PubMed PMID: 3481266.

19: Bouskela E, Donyo KA, Verbeuren TJ. Effects of Daflon 500 mg on increased microvascular permeability in normal hamsters. Int J Microcirc Clin Exp. 1995;15 Suppl 1:22-6. PubMed PMID: 8748885.

20: Veverková L, Kalac J, Jedlicka V, Wechsler J. [Analysis of surgical procedures on the vena saphena magna in the Czech Republic and an effect of Detralex during its stripping]. Rozhl Chir. 2005 Aug;84(8):410-2, 414-6. Czech. PubMed PMID: 16218350.